Abstract | PURPOSE: MATERIALS AND METHODS: A systematic search of MEDLINE®, Embase®, ACP (American College of Physicians) Journal Club, Cochrane CENTRAL (Central Register of Controlled Trials) and Cochrane Database of Systematic Reviews was performed. A secondary hand search was performed in relevant journals, references and the grey literature. The screening, quality assessment and data extraction of the retrieved articles were independently performed by 2 reviewers in duplicate. Studies that reported an angiomyolipoma response or adverse events after the treatment of sirolimus were included in the analysis. RESULTS: Four prospective nonrandomized studies involving 94 patients were included in the study. The overall response rate of angiomyolipoma was 46.8% (44 of 94) in the first year. In the second year the angiomyolipoma response rate for those patients still being treated with sirolimus was 43.5% (20 of 46) and the response rate of the patients whose sirolimus treatment was discontinued was 5% (2 of 40). The most common sirolimus related adverse reactions were stomatitis, respiratory infection, skin lesions and hyperlipidemia, while serious adverse reactions were rarely observed. CONCLUSIONS:
|
Authors | Zhu-feng Peng, Lu Yang, Ting-ting Wang, Ping Han, Zhen-hua Liu, Qiang Wei |
Journal | The Journal of urology
(J Urol)
Vol. 192
Issue 5
Pg. 1424-30
(Nov 2014)
ISSN: 1527-3792 [Electronic] United States |
PMID | 24813310
(Publication Type: Journal Article, Review, Systematic Review)
|
Copyright | Copyright © 2014 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Antibiotics, Antineoplastic
- Sirolimus
|
Topics |
- Angiomyolipoma
(complications, drug therapy)
- Antibiotics, Antineoplastic
(therapeutic use)
- Humans
- Kidney Neoplasms
(complications, drug therapy)
- Lymphangioleiomyomatosis
(complications, drug therapy)
- Sirolimus
(therapeutic use)
- Treatment Outcome
- Tuberous Sclerosis
(complications)
|